U.S. stocks are down in morning trading Friday, pulling the market back from all-time highs, as the Trump administration ...

In the highly regulated world of life sciences, quality isn’t a box to check—it’s a business imperative. For global en ...

Shares of Gilead Sciences Inc. slipped 4.28% to $109.64 Friday, on what proved to be an all-around dismal trading session for ...

This was the stock's second consecutive day of gains.

Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

Through a strategic, non-profit agreement, Gilead will supply up to two million doses of the long-acting HIV prevention drug ...

Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle civil claims that the drugmaker used speaker programs to pay kickbacks to doctors to induce them to ...

FOSTER CITY, Calif., April 24, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2025 results of operations.

Federal funding for HIV prevention could be slashed, according to The Wall Street Journal. Gilead Sciences fell 2.52% in premarket trading on the news. The company makes medication for treating ...

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term investors. See more on GILD stock here.

Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis today announced that they have entered into an exclusive option and license agreement to discover and ...